Citadel Advisors
ACET icon

Citadel Advisors’s Adicet Bio ACET Stock Holding History

Citadel Advisors’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,031
Closed -$12.5K – 12315
2025
Q1 		$12.5K Sell
1,031
-763
-43% -$10.9K ﹤0.01% 13446
2024
Q4 		$27.6K Buy
1,794
+1,375
+328% +$25.9K ﹤0.01% 12945
2024
Q3 		$9.65K Sell
419
-319
-43% -$7.14K ﹤0.01% 13246
2024
Q2 		$14.3K Buy
738
+344
+87% +$9.22K ﹤0.01% 12894
2024
Q1 		$14.8K Sell
394
-694
-64% -$28.7K ﹤0.01% 13219
2023
Q4 		$32.9K Sell
1,088
-206
-16% -$4.49K ﹤0.01% 12195
2023
Q3 		$28.4K Buy
1,294
+394
+44% +$13.9K ﹤0.01% 12323
2023
Q2 		$35K Sell
900
-138
-13% -$12.2K ﹤0.01% 12195
2023
Q1 		$95.6K Buy
1,038
+344
+50% +$43.2K ﹤0.01% 11331
2022
Q4 		$99.2K Sell
694
-881
-56% -$220K ﹤0.01% 11234
2022
Q3 		$358K Buy
+1,575
New +$400K ﹤0.01% 9195
2022
Q2 		– Sell
-1,494
Closed -$477K – 12762
2022
Q1 		$477K Sell
1,494
-850
-36% -$196K ﹤0.01% 9500
2021
Q4 		$656K Buy
+2,344
New +$402K ﹤0.01% 8994

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Citadel Advisors's ACET Position: Q1 2026 in Review

Citadel Advisors increased its Adicet Bio (ACET) stake by 254% in Q1 2026, buying an estimated $2.05M and bringing the position to 381,823 shares worth $2.6M. The position accounts for ﹤0.01% of the portfolio, ranked #5540.

Citadel Advisors first reported a position in ACET in Q1 2018 and has held it in 21 quarters since. The position peaked at $3.72M in Q3 2022. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • Citadel Advisors held 381,823 shares of Adicet Bio worth $2.6M as of Q1 2026.
  • Citadel Advisors bought 274,009 Adicet Bio shares in Q1 2026, an estimated $2.05M.
  • Adicet Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5540 holding.
  • Citadel Advisors first reported a position in Adicet Bio in Q1 2018 and has held it in 21 quarters since.
  • Citadel Advisors's Adicet Bio position peaked at $3.72M in Q3 2022.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.